Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer

Yasunobu Abe, Tetsuhide Ito, Eishi Baba, Koji Nagafuji, Ken Kawabe, Ilseung Choi, Yoshiyuki Arita, Toshihiro Miyamoto, Takanori Teshima, Shuji Nakano, Mine Harada

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

抄録

OBJECTIVE: Advanced unresectable pancreatic cancer has an extremely poor prognosis despite intensive chemotherapy. As a new therapeutic modality, we investigated nonmyeloablative allogeneic hematopoietic stem cell transplantation from a related donor. METHODS: Five patients with chemotherapy-resistant pancreatic cancer received allogeneic peripheral blood stem cell transplantation after a conditioning regimen consisting of low-dose total body irradiation and fludarabine. The prophylaxis for graft-versus-host disease consisted of mycophenolate mofetil and cyclosporine. RESULTS: The median age of the 5 patients was 54 years, and the median duration from diagnosis to nonmyeloablative allogeneic hematopoietic stem cell transplantation was 10 months. Three of the 5 patients achieved complete donor chimerism of peripheral T cells, at a median time of day 42. Acute graft-versus-host disease developed in 3 patients: grade 2 in 2 patients and grade 1 in 1. Tumor reduction was observed in 2 patients: 1 patient showed disappearance of the pancreatic tumor, and the other patient showed approximately 20% reduction of the tumor. Marked elevation of tumor necrosis factor α was observed as the tumor regressed. CONCLUSIONS: Although advanced pancreatic cancer progresses rapidly, some graft-versus-tumor effects and pivotal role of tumor necrosis factor α were suggested. To obtain the durable response, patient selection and new strategies become important.

元の言語英語
ページ(範囲)815-819
ページ数5
ジャーナルPancreas
38
発行部数7
DOI
出版物ステータス出版済み - 10 1 2009

Fingerprint

Hematopoietic Stem Cell Transplantation
Pancreatic Neoplasms
Immunotherapy
Graft vs Host Disease
Neoplasms
Tumor Necrosis Factor-alpha
Tissue Donors
Mycophenolic Acid
Peripheral Blood Stem Cell Transplantation
Drug Therapy
Chimerism
Whole-Body Irradiation
Patient Selection
Cyclosporine
T-Lymphocytes
Transplants

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

これを引用

Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer. / Abe, Yasunobu; Ito, Tetsuhide; Baba, Eishi; Nagafuji, Koji; Kawabe, Ken; Choi, Ilseung; Arita, Yoshiyuki; Miyamoto, Toshihiro; Teshima, Takanori; Nakano, Shuji; Harada, Mine.

:: Pancreas, 巻 38, 番号 7, 01.10.2009, p. 815-819.

研究成果: ジャーナルへの寄稿記事

Abe, Y, Ito, T, Baba, E, Nagafuji, K, Kawabe, K, Choi, I, Arita, Y, Miyamoto, T, Teshima, T, Nakano, S & Harada, M 2009, 'Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer', Pancreas, 巻. 38, 番号 7, pp. 815-819. https://doi.org/10.1097/MPA.0b013e3181b576ee
Abe, Yasunobu ; Ito, Tetsuhide ; Baba, Eishi ; Nagafuji, Koji ; Kawabe, Ken ; Choi, Ilseung ; Arita, Yoshiyuki ; Miyamoto, Toshihiro ; Teshima, Takanori ; Nakano, Shuji ; Harada, Mine. / Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer. :: Pancreas. 2009 ; 巻 38, 番号 7. pp. 815-819.
@article{8a03b2aea2984d5bada797e790264a74,
title = "Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer",
abstract = "OBJECTIVE: Advanced unresectable pancreatic cancer has an extremely poor prognosis despite intensive chemotherapy. As a new therapeutic modality, we investigated nonmyeloablative allogeneic hematopoietic stem cell transplantation from a related donor. METHODS: Five patients with chemotherapy-resistant pancreatic cancer received allogeneic peripheral blood stem cell transplantation after a conditioning regimen consisting of low-dose total body irradiation and fludarabine. The prophylaxis for graft-versus-host disease consisted of mycophenolate mofetil and cyclosporine. RESULTS: The median age of the 5 patients was 54 years, and the median duration from diagnosis to nonmyeloablative allogeneic hematopoietic stem cell transplantation was 10 months. Three of the 5 patients achieved complete donor chimerism of peripheral T cells, at a median time of day 42. Acute graft-versus-host disease developed in 3 patients: grade 2 in 2 patients and grade 1 in 1. Tumor reduction was observed in 2 patients: 1 patient showed disappearance of the pancreatic tumor, and the other patient showed approximately 20{\%} reduction of the tumor. Marked elevation of tumor necrosis factor α was observed as the tumor regressed. CONCLUSIONS: Although advanced pancreatic cancer progresses rapidly, some graft-versus-tumor effects and pivotal role of tumor necrosis factor α were suggested. To obtain the durable response, patient selection and new strategies become important.",
author = "Yasunobu Abe and Tetsuhide Ito and Eishi Baba and Koji Nagafuji and Ken Kawabe and Ilseung Choi and Yoshiyuki Arita and Toshihiro Miyamoto and Takanori Teshima and Shuji Nakano and Mine Harada",
year = "2009",
month = "10",
day = "1",
doi = "10.1097/MPA.0b013e3181b576ee",
language = "English",
volume = "38",
pages = "815--819",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer

AU - Abe, Yasunobu

AU - Ito, Tetsuhide

AU - Baba, Eishi

AU - Nagafuji, Koji

AU - Kawabe, Ken

AU - Choi, Ilseung

AU - Arita, Yoshiyuki

AU - Miyamoto, Toshihiro

AU - Teshima, Takanori

AU - Nakano, Shuji

AU - Harada, Mine

PY - 2009/10/1

Y1 - 2009/10/1

N2 - OBJECTIVE: Advanced unresectable pancreatic cancer has an extremely poor prognosis despite intensive chemotherapy. As a new therapeutic modality, we investigated nonmyeloablative allogeneic hematopoietic stem cell transplantation from a related donor. METHODS: Five patients with chemotherapy-resistant pancreatic cancer received allogeneic peripheral blood stem cell transplantation after a conditioning regimen consisting of low-dose total body irradiation and fludarabine. The prophylaxis for graft-versus-host disease consisted of mycophenolate mofetil and cyclosporine. RESULTS: The median age of the 5 patients was 54 years, and the median duration from diagnosis to nonmyeloablative allogeneic hematopoietic stem cell transplantation was 10 months. Three of the 5 patients achieved complete donor chimerism of peripheral T cells, at a median time of day 42. Acute graft-versus-host disease developed in 3 patients: grade 2 in 2 patients and grade 1 in 1. Tumor reduction was observed in 2 patients: 1 patient showed disappearance of the pancreatic tumor, and the other patient showed approximately 20% reduction of the tumor. Marked elevation of tumor necrosis factor α was observed as the tumor regressed. CONCLUSIONS: Although advanced pancreatic cancer progresses rapidly, some graft-versus-tumor effects and pivotal role of tumor necrosis factor α were suggested. To obtain the durable response, patient selection and new strategies become important.

AB - OBJECTIVE: Advanced unresectable pancreatic cancer has an extremely poor prognosis despite intensive chemotherapy. As a new therapeutic modality, we investigated nonmyeloablative allogeneic hematopoietic stem cell transplantation from a related donor. METHODS: Five patients with chemotherapy-resistant pancreatic cancer received allogeneic peripheral blood stem cell transplantation after a conditioning regimen consisting of low-dose total body irradiation and fludarabine. The prophylaxis for graft-versus-host disease consisted of mycophenolate mofetil and cyclosporine. RESULTS: The median age of the 5 patients was 54 years, and the median duration from diagnosis to nonmyeloablative allogeneic hematopoietic stem cell transplantation was 10 months. Three of the 5 patients achieved complete donor chimerism of peripheral T cells, at a median time of day 42. Acute graft-versus-host disease developed in 3 patients: grade 2 in 2 patients and grade 1 in 1. Tumor reduction was observed in 2 patients: 1 patient showed disappearance of the pancreatic tumor, and the other patient showed approximately 20% reduction of the tumor. Marked elevation of tumor necrosis factor α was observed as the tumor regressed. CONCLUSIONS: Although advanced pancreatic cancer progresses rapidly, some graft-versus-tumor effects and pivotal role of tumor necrosis factor α were suggested. To obtain the durable response, patient selection and new strategies become important.

UR - http://www.scopus.com/inward/record.url?scp=70349929284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349929284&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e3181b576ee

DO - 10.1097/MPA.0b013e3181b576ee

M3 - Article

VL - 38

SP - 815

EP - 819

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 7

ER -